These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26197855)

  • 41. [Treatment of Graves' disease--antithyroid drug therapy].
    Onaya T
    Nihon Rinsho; 1999 Aug; 57(8):1846-50. PubMed ID: 10483263
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Evolution of diagnostic and therapeutic criteria in Graves' disease in Spain. Comparison of the results of 2 surveys in 1987 and 1995].
    Escobar Jiménez F; Luna López V; Fernández Soto ML; Quezada Charneco M; Glinoer D
    Med Clin (Barc); 1998 Sep; 111(6):205-10. PubMed ID: 9789225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
    McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
    N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.
    García-Mayor RV; Páramo C; Luna Cano R; Pérez Mendez LF; Galofré JC; Andrade A
    J Endocrinol Invest; 1992 Dec; 15(11):815-20. PubMed ID: 1283984
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
    Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Graves' hyperthyroidism in pregnancy.
    Nguyen CT; Mestman JH
    Curr Opin Endocrinol Diabetes Obes; 2019 Oct; 26(5):232-240. PubMed ID: 31389810
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves' Disease: A Nationwide Population-Based Cohort Study.
    Song E; Kim M; Park S; Park MJ; Kim JA; Roh E; Yu JH; Kim NH; Seo JA; Kim SG; Kim NH; Choi KM; Baik SH; Yoo HJ
    Front Endocrinol (Lausanne); 2021; 12():761782. PubMed ID: 34690936
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy.
    Rotondi M; Cappelli C; Pirali B; Pirola I; Magri F; Fonte R; Castellano M; Rosei EA; Chiovato L
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3985-8. PubMed ID: 18664537
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study.
    Okosieme OE; Taylor PN; Evans C; Thayer D; Chai A; Khan I; Draman MS; Tennant B; Geen J; Sayers A; French R; Lazarus JH; Premawardhana LD; Dayan CM
    Lancet Diabetes Endocrinol; 2019 Apr; 7(4):278-287. PubMed ID: 30827829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Measuring TSH receptor antibody to influence treatment choices in Graves' disease.
    Hesarghatta Shyamasunder A; Abraham P
    Clin Endocrinol (Oxf); 2017 May; 86(5):652-657. PubMed ID: 28295509
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease.
    Nedrebo BG; Holm PI; Uhlving S; Sorheim JI; Skeie S; Eide GE; Husebye ES; Lien EA; Aanderud S
    Eur J Endocrinol; 2002 Nov; 147(5):583-9. PubMed ID: 12444889
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ; Wiersinga WM; Prummel MF
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group.
    Törring O; Tallstedt L; Wallin G; Lundell G; Ljunggren JG; Taube A; Sääf M; Hamberger B
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2986-93. PubMed ID: 8768863
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Are pituitary and thyroid function tests useful for the monitoring of antithyroid drug treatment and the post therapeutic control of Graves' disease?
    Jaffiol C; Baldet L; Castelnau P; Papachristou C; Lapinski H; Rouaud R
    Horm Res; 1987; 26(1-4):137-45. PubMed ID: 2439427
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
    Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):248-53. PubMed ID: 15314994
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A 2013 European survey of clinical practice patterns in the management of Graves' disease.
    Bartalena L; Burch HB; Burman KD; Kahaly GJ
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):115-20. PubMed ID: 25581877
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.